Oral Azvudine for hospitalised patients with COVID-19 and pre …
网页A randomized, open-label, controlled clinical trial of Azvudine tablets in the treatment of mild and common COVID-19, a pilot study
A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets ...
网页Thus, this randomized, open-label, controlled clinical trial (ChiCTR2000029853) was performed in China. A total of 20 mild and common COVID-19 patients were enrolled and randomly assigned to receive azvudine and symptomatic treatment (FNC group), or standard antiviral and symptomatic treatment (control group).
China approves first homegrown COVID antiviral - Nature
网页2022年7月26日 · China’s drug regulator granted conditional approval on Monday for an HIV drug to be used to treat COVID-19. The drug, Azvudine, developed by Chinese drugmaker Genuine Biotech, is the first oral...
Azvudine (FNC): a promising clinical candidate for COVID-19
网页2020年10月10日 · To evaluate the efficacy and safety of FNC in patients with mild and common COVID-19, we recently conducted a randomized, open-label, controlled clinical trial of FNC tablets in China ...
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in …
网页2021年12月6日 · Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it into Phase III trial for...
A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets ...
网页2020年8月13日 · This pilot study is a randomized, open, controlled clinical trial to evaluate the efficacy and safety of azvudine tablets in the treatment of COVID‐19. Our trial found that azvudine may shorten the time of nucleic acid negativity conversion of persistent mild and common COVID‐19 patient versus standard antiviral therapy.
网页Azvudine inhibited SARS-CoV-2 with the virus clearance time of about 5 days. Compared with the control group, the viral load of the Azvudine group decreased by an average of 1.56 log10 on the fifth day of medication. Azvudine was also effective against virus var-iants (Alpha, Beta, Delta, and Omicron). In terms of the safety, Azvudine (5 mg
Efficacy and safety of azvudine in patients with COVID-19: A …
网页2023年9月14日 · Azvudine can significantly increase the proportion of patients with improved clinical symptoms of COVID-19 within 5 days of treatment and achieve excellent clinical results. In terms of inhibiting COVID-19, it can inhibit the activity of COVID-19 and increase the proportion of PT-PCR negativity.
The first Chinese oral anti-COVID-19 drug Azvudine launched
网页2022年11月8日 · Azvudine was also effective against virus variants (Alpha, Beta, Delta, and Omicron). In terms of the safety, Azvudine (5 mg per person per day) was well tolerated and did not increase the risk of subjects, and the incidence of adverse events was not statistically different between the Azvudine group and the placebo group.
The first Chinese oral anti-COVID-19 drug Azvudine launched
网页2022年11月11日 · Molnupiravir is the first oral and direct-acting antiviral prodrug. The results from a phase 3, double-blind, randomized, placebo-controlled trial with a total of 1433 participants have shown that early Molnupiravir treatment reduces the risk of hospitalization or death in at-risk, unvaccinated COVID-19 adult patients.
跳至内容